Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation

Bone Marrow Transplant. 1993 Sep;12(3):209-15.

Abstract

We investigated a case of graft rejection after in vivo/ex vivo T-depleted BMT in a patient who had received a HVG-matched, GVH one locus-mismatched, MLC-negative graft from his cousin. In vivo/ex vivo T cell depletion was performed with Campath 1G (CP1G) and Campath 1M (CP1M), respectively. We identified a failure of CP1G to eradicate a CDw52- (Campath-negative) host T cell population as the main cause of treatment failure. The analysis also suggests that significant host-versus-donor reactivity prior to transplant, as detected by limiting dilution analysis, also contributed to graft rejection. The rejecting T cells were bifunctional in that they showed cytotoxic activity and were capable of inhibiting haemopoietic progenitor growth by producing inhibitory lymphokines.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibody-Dependent Cell Cytotoxicity
  • Antigens, CD / analysis*
  • Antigens, Neoplasm*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Purging
  • Bone Marrow Transplantation*
  • CD52 Antigen
  • Cells, Cultured
  • Combined Modality Therapy
  • Glycoproteins*
  • Graft Rejection / immunology*
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • Leukemia-Lymphoma, Adult T-Cell / surgery*
  • Lymphocyte Activation
  • Lymphocyte Depletion*
  • Lymphokines / pharmacology
  • Male
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocyte Subsets / transplantation

Substances

  • Antigens, CD
  • Antigens, Neoplasm
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Lymphokines